stonks4u
Sign up free
PACB logo

PACB Pacific Biosciences of California, Inc.

NASDAQ Global Select · Medical - Devices · Healthcare

$1.15
+0.00 (+0.00%)

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instr…

Market Cap: $357.19Mwww.pacb.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 16Aug 16

Quote

Day Range
$1.14 – $1.17
52-Week Range
$1.07 – $2.73
Volume
$3.91M
Market Cap
$357.19M
50-Day Avg
$1.42
200-Day Avg
$1.68
Prev Close
$1.15
Open
$1.15

Valuation & Ratios

P/E Ratio
-1.03
EPS
$-1.82
P/B Ratio
104.87
P/S Ratio
3.51
Debt/Equity
141.98
Current Ratio
6.89
Dividend Yield
+0.0%
Gross Margin
+31.7%

Returns & Efficiency

Return on Equity
-10214.5%
Return on Assets
-69.7%
FCF Yield
-20.3%
EV/EBITDA
-36.75

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$160.00M$-546.38M$-1.82
2024$154.01M$-309.85M$-1.13
2023$200.52M$-306.74M$-1.21
2022$128.30M$-314.25M$-1.40
2021$130.51M$-181.22M$-0.89

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Tue, Nov 3(in 3 months)

Consensus estimate $-0.13 per share

5of 6 quarters beat consensus

Typical surprise +26.4% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 3$-0.14 vs $-0.13miss
  • Thu, May 7$-0.03 vs $-0.17beat
  • Thu, Feb 12$-0.12 vs $-0.19beat
  • Wed, Nov 5$-0.12 vs $-0.16beat
  • Thu, Aug 7$-0.13 vs $-0.18beat
  • Thu, May 8$-0.15 vs $-0.19beat

Estimates and results for PACB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

PACBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsmarketbeat.com·6h ago·Neutral

    PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.

    View source ↗